Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term WOMEN. Found 22 abstracts

no pagination
Manne S, Kashy D, Albrecht T, Wong YN, Flamm AL, Benson AB, Miller SM, Fleisher L, Buzaglo J, Roach N, Katz M, Ross E, Collins M, Poole D, Raivitch S, Miller DM, Kinzy TG, Liu T, Meropol NJ. Knowledge, Attitudes, and Self-efficacy as Predictors of Preparedness for Oncology Clinical Trials: A Mediational Model. Medical Decision Making. 2014 May;34(4):454-63.   PMCID: PMC3991731
Huo DZ, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, Hope K, Olopade OI. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. Journal of Clinical Oncology. 2009 Mar;27(8):1184-90.   PMCID: PMC2667822
Kim HJ, Barsevick AM, Tulman L. Predictors of the Intensity of Symptoms in a Cluster in Patients With Breast Cancer. Journal of Nursing Scholarship. 2009 Jan;41(2):158-65.   PMCID: PMC2884278
Neuhausen SL, Ozcelik H, Southey MC, John EM, Godwin AK, Chung W, Iriondo-Perez J, Miron A, Santella RM, Whittemore A, Andrulis IL, Buys SS, Daly MB, Hopper JL, Seminara D, Senie RT, Terry MB, Breast Canc Family Registry; Breast Canc Family R. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Research and Treatment. 2009 Jul;116(2):379-86.   PMCID: PMC2775077
Alderman AK, Hawley ST, Waijee J, Mujahid M, Morrow M, Katz SJ. Understanding the impact of breast reconstruction on the surgical decision-making process for breast cancer. Cancer. 2008 Feb;112(3):489-94.
Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White M, Artioli G, Dudlicek L, Olopade OL. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine. 2008 Mar;10(3):161-6.
Hassett MJ, Hughes ME, Niland JC, Edge SB, Theriault RL, Wong YN, Wilson J, Carter WB, Blayney DW, Weeks JC. Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer. Journal of Clinical Oncology. 2008 Dec;26(34):5553-60.
Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. Journal of Clinical Oncology. 2008 Mar;26(8):1331-7.
Kim HJ, Barsevick AM, Tulman L, McDermott PA. Treatment-Related Symptom Clusters in Breast Cancer: A Secondary Analysis. Journal of Pain and Symptom Management. 2008 Nov;36(5):468-79.
Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. American Journal of Surgical Pathology. 2007 Jan;31(1):121-8.
Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clinical Breast Cancer. 2007 Dec;7(11):875-82.
Hawley ST, Lantz PM, Janz NK, Salem B, Morrow M, Schwartz K, Liu LH, Katz SJ. Factors associated with patient involvement in surgical treatment decision making for breast cancer. Patient education and counseling. 2007 Mar;65(3):387-95.
Morrow M, O'Sullivan MJ. The dilemma of DCIS. Breast. 2007 Dec;16:S59-S62.
Rebbeck TR, Troxel AB, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Norman S, Bunin G, DeMichele A, Berlin M, Schinnar R, Berlin JA, Strom BL. Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiology Biomarkers & Prevention. 2007 Mar;16(3):444-50.
Saeed M, Rogan E, Fernandez SV, Sheriff F, Russo J, Cavalieri E. Formation of depurinating N3Adenine and N7Guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol. International journal of cancer. 2007 Apr;120(8):1821-4.
Sauter ER, Wagner-Mann C, Ehya H, Klein-Szanto A. Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings. Cancer Detection and Prevention. 2007 Jan;31(1):50-8.
Winter WE, Maxwell GL, Tian CQ, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2007 Aug;25(24):3621-7.
Cai KQ, Klein-Szanto A, Karthik D, Edelson M, Daly MB, Ozols RF, Lynch HT, Godwin AK, Xu XX. Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecologic Oncology. 2006 Nov;103(2):719-28.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM, Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; prostate-specific antigen doubling time; mortality; surrogate endpoint. 2006 Oct;15(10):1863-70.
Bloom BS, de Pouvourville N, Chhatre S, Jayadevappa R, Weinberg D. Breast cancer treatment in clinical practice compared to best evidence and practice guidelines. British Journal of Cancer. 2004 Jan;90(1):26-30.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term WOMEN

WOMEN OVARIAN-CANCER RISK SURGERY breast cancer THERAPY ADJUVANT CHEMOTHERAPY TAMOXIFEN BRCA2 BRCA1 FATIGUE FOLLOW-UP SURVIVAL DISTRESS CARCINOMA-IN-SITU REDUCTION PREVALENCE GERMLINE MUTATIONS PENETRANCE FAMILY-HISTORY ESTROGEN-RECEPTOR STATUS BREAST-CANCER CARRIERS LUNG-CANCER CARCINOMA CONSERVING SURGERY MASTECTOMY cancer BREAST-CANCER RISK HORMONE REPLACEMENT THERAPY POSTMENOPAUSAL DIAGNOSIS Symptom clusters human glandular kallikrein 2 catechot estrogen conjugates surgical treatment HIGHLIGHTS IMMEDIATE GENE MUTATION Results No statistically significant difference in frequency of these prophylactic salpingo-oophorectomy SALPINGO-OOPHORECTOMY PREVENTION breast cancer initiation PSA measurements) and cancer-specific survival (CSS) FAILURE with BRCA1 BRCA2 genotypes or are CARRIER PROBABILITIES estrogen metabolism Ottawa Decision Support Framework IMPACT KeyWords Plus: POPULATION etiological factor we have investigated a recent cancer precursors is controversial Here women age 45-54 of either HR or NR groups RECURRENCE (T2c-4 and PSA level < 150 ng CHOICE MICE TRIAL DEATH evidence-based medicine PROSTATE-CANCER stratification were assessed in a blinded fashion RECONSTRUCTION (P-Cox = 04) The significant posttreatment PSADTs were also LOCAL THERAPY inclusion cysts and deep invaginations were found much more commonly in INFORMATION GROUP EXPERIENCE RANDOMIZED-TRIALS LOCAL RECURRENCE biomarkers CISPLATIN CANCER RISK significant predictors of CSS (P-Cox < 0001) After adjusting for T treatment 2 genotypes or reproductive history FIBROBLAST-GROWTH-FACTOR CANCER-RISK (Methods and Materials: ) under bar We analyzed posttreatment PSA FAMILY REGISTRY PARTICIPATION or in combination with 24 65-70 Gy of radiation therapy (n = 761) CANCER-SUSCEPTIBILITY GENES predictive markers OVULATION symptom management HEALTH BELIEF MODEL BILATERAL PROPHYLACTIC OOPHORECTOMY randomized treatment was a significant predictor for CSS (p(Cox) = months of adjuvant androgen deprivation (n = 753) Using an adjusted men were randomized to neoadjuvant androgen deprivation and April 1995 TUMORIGENESIS POPULATION STRATIFICATION CANCER RESIDUAL CANCER GONADOTROPINS AB Objective From analysis of pre-cancer ovarian tissues obtained from CYTOCHROME P4501B1 ovaries from surgeries due to other non-ovarian-related cancer or INTRAPERITONEAL TREATMENT ALTERNATIVES human breast epithelial cells Medical Informatics surgery PATIENT symptom assessment PHYSICIANS MANAGEMENT the risk of dying requirements for a surrogate endpoint of CSS Thus surrogate endpoint basic PREDICTORS PREFERENCES TRUNCATING BRCA1 but did not meet all of Prentice's significantly associated with CSS several studies reported the increased prophylactic oophorectomies STAGE-I SEQUENCE VARIANTS NONCARRIERS cancer (c) 2006 Elsevier Inc All rights reserved IMMUNOHISTOCHEMICAL MARKERS pathology collection of ovaries from prophylactic oophorectomies and control METABOLITES genetic testing the randomized treatment patient preference aging GENETIC POLYMORPHISMS epithelium breast cancer breast reconstruction-SEER-decision-making patients cancer clinical trials familial MECHANISM PACLITAXEL CONSENSUS DECISIONAL CONFLICT INDIVIDUALS SURGICAL ADJUVANT BREAST RISK AB (Purpose:) under bar We evaluated whether posttreatment ovarian and gonadotropin stimulation produces ovarian morphological changes ENDOMETRIAL CANCER menopause quinines Gleason score and PSA stage-all of Prentice's requirements were not
Last updated on Friday, August 14, 2020